Aligos Therapeutics Inc (ALGS) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ALGS Annual Balance Sheets →
By examining balance sheet figures across successive periods, users can identify shifts in Aligos Therapeutics Inc's financial structure and capital allocation.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Assets
Cash & cash equivalent29.98
Short-term Investments, Total24.93
Cash & Short-term Investments53.00
Other Current Assets4.72
Total Current Assets59.63
Equipment/Property/Plant Net1.59
Other Assets, Noncurrent3.34
Restricted Cash Current0.17
Operating Lease Right Of Use Asset2.58
Total Assets64.56
Liabilities
Accounts Payable, Current AC7.64
Accrued Liabilities, Current AC11.99
Deferred Revenue, Current DE0.00
Total Current Liabilities23.32
Total Long-term Debt0.00
Other liabilities, Noncurrent13.14
Operating Lease Liability Current3.61
Finance Lease Liability Current0.08
Total Liabilities32.77
Stockholders' Equity
Operating Lease Liability Noncurrent0.66
Finance Lease Liability Noncurrent-
Common Stock Value0.01
Additional Paid In Capital Common Stock696.58
Retained Earnings / Accumulated Deficit-665.24
Other Equity-0.22
Common Stockholder's Equity31.79
Total Stockholder's Equity31.79
Liabilities & Stockholder's Equity64.56
4 historic quarters locked

Sign in to unlock the full Aligos Therapeutics Inc balance sheet history.

About Aligos Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-336851

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.